Panther buying Alchemia's formerly IPO-ready cancer business
This article was originally published in Scrip
Executive Summary
Alchemia Limited planned to spin out its oncology business as Audeo Oncology through a US initial public offering in 2012, but now the Australian biotechnology company is selling its cancer drug operations to Panther Biotechnology, an acquisitive firm based in Chicago and San Diego.